MLRagent

Do not use presentational elements to obscure or distort scientific content

AI-verifiedblockerFDA guidance · non-bindingRaised as a question — a person decides

Rule

A firm-generated presentation should not use textual, graphic, or table/graph design elements that obscure or distort the scientific content — including emphasizing only favorable information, distracting from unfavorable information, or misrepresenting relationships/trends/differences/changes shown in the source data.

Check

Review typography, color, layout, and any tables/graphs for selective emphasis or visual distortion relative to the underlying data. A violation is design choices that make unfavorable information less noticeable or that misrepresent data relationships.

Escalate when

Whether a design choice crosses from legitimate emphasis into distortion is a judgment call.

Where this comes from

Section V, Q5 (prohibited practices) · page 29. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…onsultants to or who received compensation from the firm at the time of writing, editing, or contributing to the source publication Present information (e.g., excerpts, quotes, paraphrases, conclusions) from the source publication out of context Use statistical analyses or techniques to indicate clinical significance or validity of a finding not supported by the data or information in the source publication Use presentational elements to obscure or distort the scientific content, such as by using textual features and graphic design elements to emphasize only positive information or distract attention from unfavorable information, or by using tables or graphs to distort or misrepresent the relationships, trends, differences, or changes among the outcomes evaluated in the source publication Nevertheless, it is consistent with the enforcement policy outlined in this guidance for firm-generated presentations to use presentational elements and other communication techniques to help explain or illustrate the scientific content in an accurate way or to help ensure clear and prominent presentation of the recommended disclosures (see Q3). For instance, a communication that includes a firm-generated presentat…
Document
FDA guidance: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers (final)
Version
as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved
2026-09-21 from www.fda.gov
Fingerprint
a36a07e1efd950b7a2a8f6b3…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.